[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5590 Referred in Senate (RFS)]
<DOC>
115th CONGRESS
2d Session
H. R. 5590
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
June 20, 2018
Received; read twice and referred to the Committee on Finance
_______________________________________________________________________
AN ACT
To require the Secretary of Health and Human Services to provide for an
action plan on recommendations for changes under Medicare and Medicaid
to prevent opioids addictions and enhance access to medication-assisted
treatment, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Opioid Addiction Action Plan Act''.
SEC. 2. ACTION PLAN ON RECOMMENDATIONS FOR CHANGES UNDER MEDICARE AND
MEDICAID TO PREVENT OPIOIDS ADDICTIONS AND ENHANCE ACCESS
TO MEDICATION-ASSISTED TREATMENT.
(a) In General.--Not later than January 1, 2019, the Secretary of
Health and Human Services (in this section referred to as the
``Secretary''), in collaboration with the Pain Management Best
Practices Inter-Agency Task Force convened under section 101(b) of the
Comprehensive Addiction and Recovery Act of 2016 (Public Law 114-198),
shall develop an action plan that provides recommendations described in
subsection (b).
(b) Action Plan Components.--Recommendations described in this
subsection are, based on an examination by the Secretary of potential
obstacles to an effective response to the opioid crisis,
recommendations, as determined appropriate by the Secretary, on the
following:
(1) Recommendations on changes to the Medicare program
under title XVIII of the Social Security Act and the Medicaid
program under title XIX of such Act that would enhance coverage
and payment under such programs of all medication-assisted
treatment approved by the Food and Drug Administration for the
treatment of opioid addiction and other therapies that manage
chronic and acute pain and treat and minimize risk of opioid
addiction, including recommendations on changes to the Medicare
prospective payment system for hospital inpatient department
services under section 1886(d) of such Act (42 U.S.C.
1395ww(d)) and the Medicare prospective payment system for
hospital outpatient department services under section 1833(t)
of such Act (42 U.S.C. 1395l(t)) that would allow for separate
payment for such therapies, if medically appropriate and if
necessary to encourage development and adoption of such
therapies.
(2) Recommendations for payment and service delivery models
to be tested by the Center for Medicare and Medicaid Innovation
and other federally authorized demonstration projects,
including value-based models, that may encourage the use of
appropriate medication-assisted treatment approved by the Food
and Drug Administration for the treatment of opioid addiction
and other therapies that manage chronic and acute pain and
treat and minimize risk of opioid addiction.
(3) Recommendations for data collection that could
facilitate research and policy making regarding prevention of
opioid addiction and coverage and payment under the Medicare
and Medicaid programs of appropriate opioid addiction
treatments.
(4) Recommendations for policies under the Medicare program
and under the Medicaid program that can expand access for
rural, or medically underserved communities to the full range
of medication-assisted treatment approved by the Food and Drug
Administration for the treatment of opioid addiction and other
therapies that manage chronic and acute pain and treatment and
minimize risk of opioid addiction.
(5) Recommendations on changes to the Medicare program and
the Medicaid program to address coverage or payment barriers to
patient access to medical devices that are non-opioid based
treatments approved by the Food and Drug Administration for the
management of acute pain and chronic pain, for monitoring
substance use withdrawal and preventing overdoses of controlled
substances, and for treating substance use disorder.
(c) Stakeholder Meetings.--
(1) In general.--Beginning not later than 3 months after
the date of the enactment of this Act, the Secretary shall
convene a public stakeholder meeting to solicit public comment
on the components of the action plan recommendations described
in subsection (b).
(2) Participants.--Participants of meetings described in
paragraph (1) shall include representatives from the Food and
Drug Administration and National Institutes of Health,
biopharmaceutical industry members, medical researchers, health
care providers, the medical device industry, the Medicare
program, the Medicaid program, and patient advocates.
(d) Request for Information.--Not later than 3 months after the
date of the enactment of this section, the Secretary shall issue a
request for information seeking public feedback regarding ways in which
the Centers for Medicare & Medicaid Services can help address the
opioid crisis through the development of and application of the action
plan.
(e) Report to Congress.--Not later than June 1, 2019, the Secretary
shall submit to Congress, and make public, a report that includes--
(1) a summary of recommendations that have emerged under
the action plan;
(2) the Secretary's planned next steps with respect to the
action plan; and
(3) an evaluation of price trends for drugs used to reverse
opioid overdoses (such as naloxone), including recommendations
on ways to lower such prices for consumers.
(f) Definition of Medication-Assisted Treatment.--In this section,
the term ``medication-assisted treatment'' includes opioid treatment
programs, behavioral therapy, and medications to treat substance abuse
disorder.
Passed the House of Representatives June 19, 2018.
Attest:
KAREN L. HAAS,
Clerk.